Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Intracellular NAD(H) levels control motility and invasion of glioma cells.

van Horssen R, Willemse M, Haeger A, Attanasio F, Güneri T, Schwab A, Stock CM, Buccione R, Fransen JA, Wieringa B.

Cell Mol Life Sci. 2013 Jun;70(12):2175-90. doi: 10.1007/s00018-012-1249-1. Epub 2013 Jan 10.

PMID:
23307072
2.

NAMPT-mediated salvage synthesis of NAD+ controls morphofunctional changes of macrophages.

Venter G, Oerlemans FT, Willemse M, Wijers M, Fransen JA, Wieringa B.

PLoS One. 2014 May 13;9(5):e97378. doi: 10.1371/journal.pone.0097378. eCollection 2014.

3.

Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer.

Santidrian AF, LeBoeuf SE, Wold ED, Ritland M, Forsyth JS, Felding BH.

DNA Repair (Amst). 2014 Nov;23:79-87. doi: 10.1016/j.dnarep.2014.08.006. Epub 2014 Sep 26.

4.

CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.

Grozio A, Sociali G, Sturla L, Caffa I, Soncini D, Salis A, Raffaelli N, De Flora A, Nencioni A, Bruzzone S.

J Biol Chem. 2013 Sep 6;288(36):25938-49. doi: 10.1074/jbc.M113.470435. Epub 2013 Jul 23.

5.

Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD.

Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M, Leo O, So A, De Smedt T.

PLoS One. 2008 May 21;3(5):e2267. doi: 10.1371/journal.pone.0002267.

6.

Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.

Tan B, Young DA, Lu ZH, Wang T, Meier TI, Shepard RL, Roth K, Zhai Y, Huss K, Kuo MS, Gillig J, Parthasarathy S, Burkholder TP, Smith MC, Geeganage S, Zhao G.

J Biol Chem. 2013 Feb 1;288(5):3500-11. doi: 10.1074/jbc.M112.394510. Epub 2012 Dec 13.

7.

Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.

O'Brien T, Oeh J, Xiao Y, Liang X, Vanderbilt A, Qin A, Yang L, Lee LB, Ly J, Cosino E, LaCap JA, Ogasawara A, Williams S, Nannini M, Liederer BM, Jackson P, Dragovich PS, Sampath D.

Neoplasia. 2013 Dec;15(12):1314-29.

8.

NAMPT pathway is involved in the FOXO3a-mediated regulation of GADD45A expression.

Thakur BK, Lippka Y, Dittrich T, Chandra P, Skokowa J, Welte K.

Biochem Biophys Res Commun. 2012 Apr 20;420(4):714-20. doi: 10.1016/j.bbrc.2012.03.017. Epub 2012 Mar 10.

PMID:
22430142
9.

Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells.

Bowlby SC, Thomas MJ, D'Agostino RB Jr, Kridel SJ.

PLoS One. 2012;7(6):e40195. doi: 10.1371/journal.pone.0040195. Epub 2012 Jun 29.

10.

Depletion of the central metabolite NAD leads to oncosis-mediated cell death.

Del Nagro C, Xiao Y, Rangell L, Reichelt M, O'Brien T.

J Biol Chem. 2014 Dec 19;289(51):35182-92. doi: 10.1074/jbc.M114.580159. Epub 2014 Oct 29.

11.

The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.

Watson M, Roulston A, Bélec L, Billot X, Marcellus R, Bédard D, Bernier C, Branchaud S, Chan H, Dairi K, Gilbert K, Goulet D, Gratton MO, Isakau H, Jang A, Khadir A, Koch E, Lavoie M, Lawless M, Nguyen M, Paquette D, Turcotte E, Berger A, Mitchell M, Shore GC, Beauparlant P.

Mol Cell Biol. 2009 Nov;29(21):5872-88. doi: 10.1128/MCB.00112-09. Epub 2009 Aug 24.

12.

Inhibition of nicotinamide phosphoribosyltransferase modifies LPS-induced inflammatory responses of human monocytes.

Schilling E, Wehrhahn J, Klein C, Raulien N, Ceglarek U, Hauschildt S.

Innate Immun. 2012 Jun;18(3):518-30. doi: 10.1177/1753425911423853. Epub 2011 Oct 5.

PMID:
21975728
13.

Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase.

Zhang LY, Liu LY, Qie LL, Ling KN, Xu LH, Wang F, Fang SH, Lu YB, Hu H, Wei EQ, Zhang WP.

Eur J Pharmacol. 2012 Jan 15;674(2-3):163-70. doi: 10.1016/j.ejphar.2011.11.017. Epub 2011 Nov 19.

PMID:
22119381
14.

Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil.

Bi TQ, Che XM, Liao XH, Zhang DJ, Long HL, Li HJ, Zhao W.

Oncol Rep. 2011 Nov;26(5):1251-7. doi: 10.3892/or.2011.1378. Epub 2011 Jul 4.

PMID:
21743967
15.

Nampt expression increases during osteogenic differentiation of multi- and omnipotent progenitors.

Li Y, He J, He X, Li Y, Lindgren U.

Biochem Biophys Res Commun. 2013 Apr 26;434(1):117-23. doi: 10.1016/j.bbrc.2013.02.132. Epub 2013 Mar 26.

PMID:
23537654
16.
17.

Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1.

Nakahata Y, Sahar S, Astarita G, Kaluzova M, Sassone-Corsi P.

Science. 2009 May 1;324(5927):654-7. doi: 10.1126/science.1170803. Epub 2009 Mar 12.

18.

Nicotinamide phosphoribosyltransferase/sirtuin 1 pathway is involved in human immunodeficiency virus type 1 Tat-mediated long terminal repeat transactivation.

Zhang HS, Sang WW, Wang YO, Liu W.

J Cell Biochem. 2010 Aug 15;110(6):1464-70. doi: 10.1002/jcb.22704.

PMID:
20506278
19.

NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism.

Burgos ES.

Curr Med Chem. 2011;18(13):1947-61. Review.

PMID:
21517777
20.

[Mechanism of Nampt gene expression regulation].

Huang R, Wang ZR, Sun Y, Zhang G, Lu YP.

Yi Chuan. 2012 Dec;34(12):1561-9. Review. Chinese.

PMID:
23262103
Items per page

Supplemental Content

Write to the Help Desk